HomeInsightsStock Comparison

Aurobindo Pharma Ltd vs Cipla Ltd Stock Comparison

Aurobindo Pharma Ltd vs Cipla Ltd Stock Comparison

Last Updated on: Apr 27, 2025

Key Highlights

  • The Latest Trading Price of Aurobindo Pharma Ltd is ₹ 1217 as of 25 Apr 15:30.
  • The P/E Ratio of Aurobindo Pharma Ltd changed from 8.5 on March 2020 to 20.1 on March 2024 . This represents a CAGR of 18.78% over 5 yearsThe P/E Ratio of Cipla Ltd changed from 22 on March 2020 to 29.3 on March 2024 . This represents a CAGR of 5.90% over 5 years.
  • The Market Cap of Aurobindo Pharma Ltd changed from ₹ 24202 crore on March 2020 to ₹ 63835 crore on March 2024 . This represents a CAGR of 21.41% over 5 yearsThe Market Cap of Cipla Ltd changed from ₹ 34103 crore on March 2020 to ₹ 120673 crore on March 2024 . This represents a CAGR of 28.75% over 5 years.
  • The revenue of Aurobindo Pharma Ltd for the Dec '24 is ₹ 8137 crore as compare to the Sep '24 revenue of ₹ 7932 crore. This represent the growth of 2.58% The revenue of Cipla Ltd for the Dec '24 is ₹ 7294 crore as compare to the Sep '24 revenue of ₹ 7241 crore. This represent the growth of 0.73%.
  • The ebitda of Aurobindo Pharma Ltd for the Dec '24 is ₹ 1736 crore as compare to the Sep '24 ebitda of ₹ 1702 crore. This represent the growth of 2.02% The ebitda of Cipla Ltd for the Dec '24 is ₹ 2210 crore as compare to the Sep '24 ebitda of ₹ 2076 crore. This represent the growth of 6.47%.
  • The net profit of Aurobindo Pharma Ltd changed from ₹ 569.71 crore to ₹ 845.57 crore over 7 quarters. This represents a CAGR of 25.31% The net profit of Cipla Ltd changed from ₹ 996.58 crore to ₹ 1583 crore over 7 quarters. This represents a CAGR of 30.30% .
  • The Dividend Payout of Aurobindo Pharma Ltd changed from 9.37 % on March 2020 to 13.49 % on March 2024 . This represents a CAGR of 7.56% over 5 yearsThe Dividend Payout of Cipla Ltd changed from 14.24 % on March 2020 to 25.74 % on March 2024 . This represents a CAGR of 12.57% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Aurobindo Pharma Ltd

  • Aurobindo Pharma Limited (APL), one of the world's top 5 manufacturers of semi synthetic penicillins was incorporated in 26th December 1986 as a private limited company.
  • Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it.
  • APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations.
  • The company's robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindo's products.
  • APL is running with 24 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped 9 R&D facilities.

About Cipla Ltd

  • Cipla Ltd is one of the leading pharmaceutical companies in India.
  • The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
  • Cipla's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.
  • With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets.
  • Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Ltd was incorporated in the year 1935 with the name Chemical, Industrial & Pharmaceutical Laboratories Ltd.

Aurobindo Pharma Ltd News Hub

News

CuraTeQ Biologics s.r.o. receives positive opinion for biosimilar Dazublys' from EMA

CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma, announc...

Read more

26 Apr 2025 13:58

News

Aurobindo Pharma rallies after arm receives USFDA nod for Dasatinib tablets

The drug is bioequivalent and therapeutically equivalent to the reference listed drug (RLD...

Read more

23 Apr 2025 12:05

News

Aurobindo Pharma rallies after receiving USFDA nod for Rivaroxaban tablets

The said drug is bioequivalent and therapeutically equivalent to the reference listed drug...

Read more

15 Apr 2025 10:07

News

Aurobindo Pharma gets USFDA nod for Rivaroxaban tablets

The said drug is bioequivalent and therapeutically equivalent to the reference listed drug...

Read more

14 Apr 2025 08:59

News

USFDA inspects Aurobindo Pharma's Raleigh Plant in North Carolina

Aurobindo Pharma announced that the United States Food and Drug Administration (USFDA) has...

Read more

11 Apr 2025 15:22

News

CuraTeQ Biologics completes Phase 1 study of denosumab biosimilar, BP16

CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, announced that its denos...

Read more

09 Apr 2025 20:47

Cipla Ltd News Hub

News

Cipla's Goa API facility receives VAI status from USFDA

According to an exchange filing dated 20 January 2025, the USFDA conducted an inspection o...

Read more

21 Apr 2025 11:32

News

Cipla allots 23,282 equity shares under ESOS

Cipla has allotted 23,282 fully paid-up equity shares of Rs 2 each, pursuant to exercise o...

Read more

17 Apr 2025 16:12

News

Cipla receives USFDA approval for Protein-bound Paclitaxel for Injectable Suspension

Cipla has received final approval from the United States Food and Drug Administration (USF...

Read more

11 Apr 2025 09:27

News

Cipla jumps on receiving approval from USFDA for protein-bound Paclitaxel

Cipla's formulation is an AB-rated therapeutic equivalent of Abraxane and is indicated for...

Read more

11 Apr 2025 10:12

News

Cipla to table results

Cipla will hold a meeting of the Board of Directors of the Company on 13 May 2025. Powered...

Read more

08 Apr 2025 09:40

News

USFDA classifies cGMP inspection of Cipla's Virgonagar facility as VAI

Cipla has classified its current Good Manufacturing Practices (cGMP) inspection of the com...

Read more

08 Feb 2025 11:16

SWOT Analysis Of Cipla Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Aurobindo Pharma Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Cipla Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Aurobindo Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Aurobindo Pharma Ltd and Cipla Ltd

Which company has a larger market capitalization, Aurobindo Pharma Ltd or Cipla Ltd?

Market cap of Aurobindo Pharma Ltd is 71,358 Cr while Market cap of Cipla Ltd is 123,201 Cr

What are the key factors driving the stock performance of Aurobindo Pharma Ltd and Cipla Ltd?

The stock performance of Aurobindo Pharma Ltd and Cipla Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aurobindo Pharma Ltd and Cipla Ltd?

As of April 27, 2025, the Aurobindo Pharma Ltd stock price is INR ₹1217.85. On the other hand, Cipla Ltd stock price is INR ₹1525.5.

How do dividend payouts of Aurobindo Pharma Ltd and Cipla Ltd compare?

To compare the dividend payouts of Aurobindo Pharma Ltd and Cipla Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions